Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2021-04-13 Governance Information
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
9_Pharmena_Oświadczenie_RN_audytor_komitet audytu
Governance Information Classification · 95% confidence The document is titled "OŚWIADCZENIE DOTYCZĄCE POLITYKI WYBORU FIRMY AUDYTORSKIEJ" (Statement Regarding the Policy for Selecting the Audit Firm) and includes a section on the Audit Committee ("OŚWIADCZENIE W SPRAWIE KOMITETU AUDYTU"). It details compliance with regulations regarding the selection, independence, and rotation of the audit firm, as well as the functioning of the Audit Committee. This content strongly aligns with corporate governance and internal control reporting, specifically concerning the audit function. Among the provided definitions, 'Audit Report / Information' (AR) covers standalone audit reports and applied accounting principles, while 'Governance Information' (CGR) covers internal rules, board structure, and governance practices. Since this document focuses on the *policy* and *oversight* related to the audit function and the Audit Committee's compliance, it fits best under Governance Information (CGR). It is not the actual audit report (AR) nor a general management report (MDA).
2021-04-13 Polish
8_Pharmena_Ocena RN_SF za 2020_final
Board/Management Information Classification · 99% confidence The document is titled 'OCENA RADY NADZORCZEJ PHARMENA S.A. DOTYCZĄCA SPRAWOZDANIA Z DZIAŁALNOŚCI GRUPY KAPITAŁOWEJ PHARMENA S.A. I PHARMENA S.A. ZA 2020 ROK, JEDNOSTKOWEGO SPRAWOZDANIA FINANSOWEGO PHARMENA S.A. I SKONSOLIDOWANEGO SPRAWOZDANIA FINANSOWEGO GRUPY KAPITAŁOWEJ PHARMENA S.A. ZA ROK ZAKOŃCZONY 31 GRUDNIA 2020 ROKU' (Assessment of the Supervisory Board of PHARMENA S.A. regarding the Management Board's Report on the activities... for 2020, the Individual Financial Statement... and the Consolidated Financial Statement... for the year ended December 31, 2020). This document is an assessment/opinion issued by the Supervisory Board concerning the Annual Report and Financial Statements for the year 2020. It is not the Annual Report (10-K) itself, nor is it a standalone Audit Report (AR). It is a formal document related to the review of annual financial reporting by the board, which aligns closely with the scope covered by an Audit Report or general regulatory review documentation, but specifically focuses on the board's opinion on the annual filings. Given the options, 'Audit Report / Information' (AR) is the closest fit for a document detailing the formal review and opinion on the annual financial statements and management report, especially since the document explicitly mentions reviewing the auditor's findings ('zapoznała się z przedstawionymi przez Audytora... wynikami przeprowadzonego badania'). It is a formal review/assessment document related to the annual reporting cycle.
2021-04-13 Polish
7_Pharmena_inform_zarządu_ws wyboru_audytora_2020
Audit Report / Information Classification · 98% confidence The document is titled "INFORMACJA ZARZĄDU PHARMENA S.A. SPORZĄDZONA NA PODSTAWIE OŚWIADCZENIA RADY NADZORCZEJ W SPRAWIE PODMIOTU UPRAWNIONEGO DO BADANIA SPRAWOZDAŃ FINANSOWYCH" (Information from the Management Board of PHARMENA S.A. prepared based on the Supervisory Board's statement regarding the entity authorized to audit financial statements). The content explicitly discusses the selection of the auditor (BDO Sp. z o.o.) for the annual financial statements for the year 2020, compliance with auditing standards, and related policies. This directly relates to the audit process and the resulting report, but it is a statement *about* the audit process rather than the full audit report itself. Given the definitions, 'Audit Report / Information (AR)' covers standalone audit reports and applied accounting principles. This document is a formal declaration confirming the auditor's qualifications and appointment, which falls under the scope of audit-related information, making AR the most appropriate classification over a general regulatory filing (RNS). The document is short and specific to the audit confirmation. FY 2020
2021-04-13 Polish
6_Pharmena_oświadczenie_zarządu-jedns_2020
Management Reports Classification · 95% confidence The document text is titled "OŚWIADCZENIE ZARZĄDU W SPRAWIE RZETELNOŚCI SPORZĄDZENIA SPRAWOZDANIA FINANSOWEGO" (Management Statement on the Reliability of the Financial Statement Preparation) and includes a statement from the Management Board regarding the truthfulness and fairness of the consolidated financial statements and the Management Board's Report on Operations. This type of formal declaration, often included within or accompanying annual/interim reports, relates directly to the content and integrity of the financial reporting. Given the content focuses specifically on the management's assertion about the accuracy of the financial statements and operational report, it aligns most closely with the content found in a comprehensive financial report structure, such as an Annual Report (10-K) or an Interim Report (IR). However, since this is a specific declaration section, and not the full report itself, and it deals with the management's explanation of results and outlook (even if brief), it strongly suggests content related to the Management's Discussion and Analysis (MDA) section, which covers management's explanation of financial results and business trends. Since the document is very short (1047 chars) and appears to be an excerpt or a specific signed declaration often found within a larger filing, classifying it as MDA (Management's detailed explanation) is appropriate as it is a direct management commentary on the financial statements and operations. If it were a full report, 10-K or IR would be better, but as a standalone signed statement about the report's quality, MDA fits the context of management commentary.
2021-04-13 Polish
5_Pharmena_Sprawozdanie z działalności_za 2020_podpisane
Annual Report Classification · 95% confidence The document is a 'Sprawozdanie Zarządu' (Management Report) for Pharmena S.A. for the year 2020. It contains a detailed table of contents covering financial data, business activities, corporate governance, shareholding structures, and management commentary. This structure is characteristic of an Annual Report (10-K equivalent in the Polish market context), as it provides a comprehensive overview of the company's yearly performance and financial position. FY 2020
2021-04-13 Polish
4_Pharmena sprawozdanie finansowe_za 2020
Annual Report Classification · 100% confidence The document is a comprehensive financial report for Pharmena S.A. for the year ended December 31, 2020. It contains detailed financial statements (Statement of Profit or Loss, Statement of Comprehensive Income, Statement of Cash Flows, Statement of Financial Position, and Statement of Changes in Equity) along with extensive explanatory notes. Since it covers a full fiscal year and includes audited financial statements, it is classified as an Annual Report (10-K). FY 2020
2021-04-13 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.